Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
MWN-AI** Summary
Bluejay Diagnostics, Inc. has announced a significant milestone in its SYMON-II pivotal clinical trial, completing the enrollment of 624 patients out of a target of 750 within the study. This trial evaluates the Symphony™ platform for interleukin-6 (IL-6) testing, focusing on its application in critical care to assess patient acuity for sepsis triage and monitoring. The company anticipates completing patient enrollment within the next 2 to 3 months, contingent on site activity and patient flow, emphasizing that the inclusion and exclusion criteria have not significantly hindered the enrollment process.
Neil Dey, CEO of Bluejay Diagnostics, expressed his satisfaction with the team's performance, noting that reaching 624 patients positions the company well for the next steps, aimed at generating valuable clinical insights to enhance patient outcomes in critical care. The Symphony™ IL-6 Test seeks to provide rapid, near-patient results, aiding healthcare professionals in prompt decision-making in acute care settings.
Following the completion of enrollment, Bluejay is set to advance toward clinical validation and regulatory submission activities, supporting its broader strategy of enhancing near-patient testing capabilities. Notably, the Symphony IL-6 Test, currently Bluejay's lead product candidate, is being developed to deliver accurate results in approximately 20 minutes.
The SYMON Clinical Study Program includes multiple studies, such as SYMON-I and SYMON-III, aimed at validating IL-6 levels and assessing infection severity. Notably, Bluejay Diagnostics is still awaiting regulatory clearance from the U.S. Food and Drug Administration before marketing the Symphony System in the United States. The press release included forward-looking statements about the company's expectations, highlighting the inherent uncertainties in clinical research and market conditions. For further information, Bluejay Diagnostics maintains a corporate website at www.bluejaydx.com.
MWN-AI** Analysis
Bluejay Diagnostics, Inc. recently announced a significant milestone in its SYMON-II clinical trial, completing 624 out of an anticipated 750 patient enrollments. This advancement underscores the efficacy of Bluejay’s Symphony™ IL-6 test, a pivotal development in sepsis triage and monitoring in critical care. The completion of the trial is crucial for Bluejay to validate its testing capabilities, which, if successful, could revolutionize near-patient diagnostics and lead to timely interventions in critical situations.
From an investment perspective, Bluejay appears to be on a promising trajectory. The successful enrollment rates and the lack of significant exclusions from the study suggest strong protocol adherence and cooperation from clinical sites. This bodes well for achieving the target enrollment in the next two to three months, potentially propelling the company forward in its regulatory submission process to the FDA. Successful FDA approval would unlock a substantial commercial market for the Symphony™ IL-6 test and enhance Bluejay's revenue prospects.
Investors should note the inherent risks associated with biotech investments, particularly the uncertainty regarding regulatory approval timelines and clinical trial outcomes. However, the positive momentum from current enrollment rates may lead to favorable market sentiment and a potential increase in stock valuation as the Company approaches significant milestones.
For those already holding shares or considering an entry point, it may be wise to observe how Bluejay manages the upcoming phases of clinical validation and its interactions with regulatory bodies. Targeting key acquisition thresholds related to enrollment completion and FDA activity could yield strategic trading opportunities. Investors are encouraged to stay informed about the firm’s progress, as developments may substantially impact stock performance in the near term.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company’s Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring.
The SYMON-II study has a target enrollment of 750 patients, and the Company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow.
Importantly, the study’s inclusion and exclusion criteria have not caused a significant number of patients to be excluded from enrollment.
“This milestone reflects the strong execution by our clinical team and the continued commitment of our investigators and clinical partners,” said Neil Dey, CEO of Bluejay Diagnostics. “Reaching 624 enrolled patients positions us well to complete enrollment in the near term, bringing us closer to delivering meaningful clinical insights that could improve outcomes in critical care. We are particularly encouraged by the fact that study’s inclusion and exclusion criteria have not caused a significant number of patients to be excluded from enrollment.”
The SYMON-II trial is designed to support the clinical validation of Bluejay’s Symphony™ IL-6 test, which aims to provide rapid, near-patient results to aid clinicians in assessing patient severity and guiding timely decision-making in acute care environments.
With enrollment nearing completion, Bluejay anticipates progressing toward the next phases of clinical validation and regulatory submission activities, consistent with its broader strategy to advance near-patient testing and real-time monitoring in critical care settings, where timely decision-making is essential.
About the Symphony IL-6 Test:
The Symphony™ Test platform is designed to determine patient acuity for triage and monitoring based on the measurement of a specific biomarker. The Symphony™ IL-6 Test to determine patient acuity for sepsis triage and monitoring (“Symphony™ IL-6 Test”) is currently Bluejay’s lead product candidate.
Note: Investigational device. Limited by United States law to investigational use.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com
FAQ**
How does Bluejay Diagnostics Inc. (BJDX) plan to leverage the results from the SYMON-II Trial to enhance its position in the market for rapid, near-patient testing in critical care settings?
What specific plans does Bluejay Diagnostics Inc. (BJDX) have for regulatory submission activities following the completion of patient enrollment in the SYMON-II Trial?
Given that the Symphony IL-6 Test is currently investigational, what are the anticipated next steps for Bluejay Diagnostics Inc. (BJDX) to secure FDA clearance for commercial use?
How does Bluejay Diagnostics Inc. (BJDX) intend to address potential risks and uncertainties that could affect the market introduction of its Symphony™ platform based on the findings from the SYMON-II Trial?
**MWN-AI FAQ is based on asking OpenAI questions about Bluejay Diagnostics Inc. (NASDAQ: BJDX).
NASDAQ: BJDX
BJDX Trading
110.19% G/L:
$4.54 Last:
64,710,382 Volume:
$6.12 Open:
